Literature DB >> 28647917

Novel Endpoints for Heart Failure Clinical Trials.

Carine E Hamo1, Mihai Gheorghiade2, Javed Butler3.   

Abstract

PURPOSE OF REVIEW: With the growing prevalence of heart failure, there is a particular need to develop new pharmacologic treatments that can improve outcomes. While there are several approved therapies for heart failure with reduced ejection fraction, there is currently no approved agent for those with preserved ejection fraction. The current review aimed to explore the utility of alternate endpoints to mortality and hospitalization. RECENT
FINDINGS: There is increased interest in the use of alternative endpoints such as functional status and quality of life for heart failure drug development to focus on patients feeling better in addition to improving outcomes. This should ideally be measured using objective as well as subjective parameters. While mortality and hospitalization remain important endpoints for clinical trials in heart failure, other more patient-centered outcomes are attractive alternatives yet how to best incorporate these in a trial setting remains to be elucidated.

Entities:  

Keywords:  Clinical trial; Endpoint; Functional status; Heart failure; Quality of life

Mesh:

Year:  2017        PMID: 28647917     DOI: 10.1007/s11897-017-0334-z

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  50 in total

1.  The 6-minute walk test and prognosis in chronic heart failure--the available evidence.

Authors:  R Sharma; S D Anker
Journal:  Eur Heart J       Date:  2001-03       Impact factor: 29.983

2.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

Review 3.  Trials of implantable monitoring devices in heart failure: which design is optimal?

Authors:  William T Abraham; Wendy G Stough; Ileana L Piña; Cecilia Linde; Jeffrey S Borer; Gaetano M De Ferrari; Roxana Mehran; Kenneth M Stein; Alphons Vincent; Jay S Yadav; Stefan D Anker; Faiez Zannad
Journal:  Nat Rev Cardiol       Date:  2014-08-12       Impact factor: 32.419

4.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.

Authors:  William T Abraham; Philip B Adamson; Robert C Bourge; Mark F Aaron; Maria Rosa Costanzo; Lynne W Stevenson; Warren Strickland; Suresh Neelagaru; Nirav Raval; Steven Krueger; Stanislav Weiner; David Shavelle; Bradley Jeffries; Jay S Yadav
Journal:  Lancet       Date:  2011-02-19       Impact factor: 79.321

5.  Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.

Authors:  James P Daubert; Wojciech Zareba; David S Cannom; Scott McNitt; Spencer Z Rosero; Paul Wang; Claudio Schuger; Jonathan S Steinberg; Steven L Higgins; David J Wilber; Helmut Klein; Mark L Andrews; W Jackson Hall; Arthur J Moss
Journal:  J Am Coll Cardiol       Date:  2008-04-08       Impact factor: 24.094

6.  The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.

Authors:  G H Guyatt; M J Sullivan; P J Thompson; E L Fallen; S O Pugsley; D W Taylor; L B Berman
Journal:  Can Med Assoc J       Date:  1985-04-15       Impact factor: 8.262

Review 7.  State of the art: using natriuretic peptide levels in clinical practice.

Authors:  Alan Maisel; Christian Mueller; Kirkwood Adams; Stefan D Anker; Nadia Aspromonte; John G F Cleland; Alain Cohen-Solal; Ulf Dahlstrom; Anthony DeMaria; Salvatore Di Somma; Gerasimos S Filippatos; Gregg C Fonarow; Patrick Jourdain; Michel Komajda; Peter P Liu; Theresa McDonagh; Kenneth McDonald; Alexandre Mebazaa; Markku S Nieminen; W Frank Peacock; Marco Tubaro; Roberto Valle; Marc Vanderhyden; Clyde W Yancy; Faiez Zannad; Eugene Braunwald
Journal:  Eur J Heart Fail       Date:  2008-08-29       Impact factor: 15.534

Review 8.  Selection of endpoints for heart failure clinical trials.

Authors:  Luisa Zanolla; Piero Zardini
Journal:  Eur J Heart Fail       Date:  2003-12       Impact factor: 15.534

Review 9.  Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency.

Authors:  Stefan D Anker; Stefan Schroeder; Dan Atar; Jeroen J Bax; Claudio Ceconi; Martin R Cowie; Adam Crisp; Fabienne Dominjon; Ian Ford; Hossein-Ardeschir Ghofrani; Savion Gropper; Gerhard Hindricks; Mark A Hlatky; Richard Holcomb; Narimon Honarpour; J Wouter Jukema; Albert M Kim; Michael Kunz; Martin Lefkowitz; Chantal Le Floch; Ulf Landmesser; Theresa A McDonagh; John J McMurray; Bela Merkely; Milton Packer; Krishna Prasad; James Revkin; Giuseppe M C Rosano; Ransi Somaratne; Wendy Gattis Stough; Adriaan A Voors; Frank Ruschitzka
Journal:  Eur J Heart Fail       Date:  2016-04-12       Impact factor: 15.534

10.  Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document.

Authors:  Faiez Zannad; Angeles Alonso Garcia; Stefan D Anker; Paul W Armstrong; Gonzalo Calvo; John G F Cleland; Jay N Cohn; Kenneth Dickstein; Michael J Domanski; Inger Ekman; Gerasimos S Filippatos; Mihai Gheorghiade; Adrian F Hernandez; Tiny Jaarsma; Joerg Koglin; Marvin Konstam; Stuart Kupfer; Aldo P Maggioni; Alexandre Mebazaa; Marco Metra; Christina Nowack; Burkert Pieske; Ileana L Piña; Stuart J Pocock; Piotr Ponikowski; Giuseppe Rosano; Luis M Ruilope; Frank Ruschitzka; Thomas Severin; Scott Solomon; Kenneth Stein; Norman L Stockbridge; Wendy Gattis Stough; Karl Swedberg; Luigi Tavazzi; Adriaan A Voors; Scott M Wasserman; Holger Woehrle; Andrew Zalewski; John J V McMurray
Journal:  Eur J Heart Fail       Date:  2013-06-19       Impact factor: 15.534

View more
  3 in total

Review 1.  Clinical Studies of Cell Therapy in Cardiovascular Medicine: Recent Developments and Future Directions.

Authors:  Monisha N Banerjee; Roberto Bolli; Joshua M Hare
Journal:  Circ Res       Date:  2018-07-06       Impact factor: 17.367

2.  Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure.

Authors:  Ana Elisa M Martinelli; Raul C Maranhão; Priscila O Carvalho; Fatima R Freitas; Bruna M O Silva; Milena N C Curiati; Roberto Kalil Filho; Antonio Carlos Pereira-Barretto
Journal:  Lipids Health Dis       Date:  2018-10-20       Impact factor: 3.876

3.  Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE-FMR trial.

Authors:  Muhammad Shahzeb Khan; Tariq Jamal Siddiqi; Javed Butler; Tim Friede; Wayne C Levy; Klaus K Witte; Janusz Lipiecki; Horst Sievert; Andrew J Stewart Coats
Journal:  ESC Heart Fail       Date:  2021-02-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.